Australia markets open in 1 hour 50 minutes

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.02260.0000 (0.00%)
At close: 11:59AM EDT

Entheon Biomedical Corp.

999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5

Full-time employees2

Key executives

NameTitlePayExercisedYear born
Mr. Timothy KoPres, CEO & Director97.26kN/A1986
Dr. Andrew Peter Hegle Ph.D.Chief Science Officer, Director of Operations & Director87.26kN/A1979
Mr. Soo-Whan KimInterim Chief Financial OfficerN/AN/AN/A
Dr. Brian E. Jahns Pharm.D.Chief Bus. OfficerN/AN/AN/A
Ms. Kelly PladsonCorp. Sec.N/AN/A1983
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.

Corporate governance

Entheon Biomedical Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.